Repurposed Drugs for Healthy Aging

How Can Network Medicine Identify Drugs That Target Aging?

Biological aging does not arise from a single defective pathway. It involves interacting processes such as genomic instability, impaired cellular recycling, altered nutrient sensing, mitochondrial dysfunction, cellular senescence, chronic inflammation, and disrupted communication between tissues. Network-based research represents these connections computationally, allowing investigators to look for drugs whose known biological targets overlap with several aging-related pathways.

This systems-level approach can reveal candidates that might be missed when researchers examine one protein at a time. It is primarily a prioritization method: a strong network association generates a testable hypothesis, not proof that a medicine changes aging in patients. Laboratory experiments, dose-finding studies, controlled clinical trials, and long-term safety monitoring are still necessary before clinical use could be justified.

Why Are Researchers Repurposing Existing Medicines for Healthy Aging?

Drug repurposing investigates whether a medicine developed for one condition could treat another. Researchers can draw on existing information about pharmacology, metabolism, contraindications, and common adverse effects. This may reduce uncertainty during early development, although a new indication can require different doses, treatment durations, or patient populations.

Aging research presents an additional challenge because treatment might continue for years in people who do not have an acute illness. Even uncommon adverse effects could outweigh uncertain preventive benefits when exposure is prolonged. Trials therefore need clinically meaningful outcomes, suitable comparison groups, and careful monitoring rather than relying only on molecular biomarkers or changes observed in cells and animals.

Do Any Medicines Currently Have Approval to Slow Human Aging?

Several established drugs are being studied for possible effects on pathways connected to aging, but modifying a pathway does not necessarily improve survival, function, or quality of life. Researchers must also distinguish treatment of age-related diseases from treatment of aging itself. A medicine may benefit people with a diagnosed condition while offering no favorable benefit-risk balance to healthy adults.

Patients should not obtain prescription medicines or unregulated products for self-directed longevity treatment. Drug interactions, organ impairment, pregnancy, and underlying illness can substantially alter risk. For now, vaccination, physical activity, adequate sleep, nutritious eating, avoiding tobacco, and evidence-based control of blood pressure, cholesterol, and diabetes have much stronger clinical foundations for supporting healthy aging.